The 10 pharma companies expected to spend the most on R&D in 2024

Johnson & Johnson and Roche are forecasted to be the top spenders on research and development in 2024, according to a new report by Evaluate Pharma.

Evaluate Pharma offers clients forecasts of the pharma industry in its annual World Preview.

The top 10 R&D spenders for 2024:

1. Johnson & Johnon ($9.9 billion)

2. Roche ($9.9 billion)

3. Merck ($9.2 billion)

4. Novartis ($9.2 billion)

5. Pfizer ($8.9 billion)

6. GlaxoSmithKline ($6.8 billion)

7. Bristol-Myers Squibb ($6.7 billion)

8. Sanofi ($6.7 billion)

9. Eli Lilly ($6.1 billion)

10. AstraZeneca ($5.9 billion)

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

/30116360/HR_Homepage_300x250-1

/30116360/HR_Homepage_300x250-2